211 related articles for article (PubMed ID: 17301975)
1. Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation.
Medeiros BC; Chun K; Kamel-Reid S; Lipton J
Am J Hematol; 2007 Aug; 82(8):758-60. PubMed ID: 17301975
[TBL] [Abstract][Full Text] [Related]
2. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
3. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
4. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
5. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
6. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.
Mohamed AN; Pemberton P; Zonder J; Schiffer CA
Clin Cancer Res; 2003 Apr; 9(4):1333-7. PubMed ID: 12684401
[TBL] [Abstract][Full Text] [Related]
7. An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment.
Rowe LR; Brothman AR; Nibley WE; Gaffney MR; Chen Z
Cancer Genet Cytogenet; 2007 Apr; 174(1):54-6. PubMed ID: 17350467
[TBL] [Abstract][Full Text] [Related]
8. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
Cho BS; Kim HJ; Lee S; Eom KS; Min WS; Lee JW; Kim CC
Eur J Haematol; 2007 Aug; 79(2):170-3. PubMed ID: 17608710
[TBL] [Abstract][Full Text] [Related]
9. [Autogeneic peripheral blood hemopoietic stem cell transplantation for chronic myeloid leukemia with imatinib mesylate-induced negative Philadelphia chromosome].
Meng FY; Sun J; Liu QF; Xu D; Yang LJ; Song LL; Liu XL; Xu B; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2003 Dec; 23(12):1301-2, 1306. PubMed ID: 14678896
[TBL] [Abstract][Full Text] [Related]
10. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Medina J; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Rios MB; Hayes K; Cortes J
Cancer; 2003 Nov; 98(9):1905-11. PubMed ID: 14584073
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis.
Koh LP; Hwang WY; Chuah CT; Linn YC; Goh YT; Tan CH; Ng HJ; Tan PH
Bone Marrow Transplant; 2003 Feb; 31(4):305-8. PubMed ID: 12621468
[TBL] [Abstract][Full Text] [Related]
12. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.
Lin Y; Bruyère H; Horsman DE; Pantzar T; Barnett MJ; Hogge DE; Nevill TJ; Nantel SH; Sutherland HJ; Toze CL; Shepherd JD; Lavoie JC; Song KW; Smith CA; Forrest DL
Cancer Genet Cytogenet; 2006 Oct; 170(1):16-23. PubMed ID: 16965950
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.
Perseghin P; Gambacorti-Passerini C; Tornaghi L; Dassi M; Pioltelli P; Parma M; Colnaghi F; Giudici G; Elli E; Fumagalli M; Ponchio L; Biondi A; Pogliani EM
Transfusion; 2005 Jul; 45(7):1214-20. PubMed ID: 15987369
[TBL] [Abstract][Full Text] [Related]
14. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
Simon W; Segel GB; Lichtman MA
Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
[TBL] [Abstract][Full Text] [Related]
15. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
Staber PB; Brezinschek R; Linkesch W; Sill H; Neumeister P
Haematologica; 2003 Aug; 88(8):ECR29. PubMed ID: 12935988
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
17. [Allogeneic stem cell transplantation for patients with Philadelphia positive leukemia resistant to imatinib].
Han W; Liu KY; Xu LP; Chen H; Liu DH; Chen YH; Zhang XH; Zhang YC; Chen Y; Wang Y; Wang J; Lu DP; Huang XJ
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1974-7. PubMed ID: 19062738
[TBL] [Abstract][Full Text] [Related]
18. [Sustained complete molecular remission after cessation of imatinib mesylate treatment in a patient with relapsed chronic myelogenous leukemia after allogeneic stem cell transplantation].
Igarashi T; Hayashi T; Yasui H; Ikeda H; Takahashi T; Ishida T; Shinomura Y
Rinsho Ketsueki; 2012 Feb; 53(2):215-8. PubMed ID: 22450581
[TBL] [Abstract][Full Text] [Related]
19. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
[TBL] [Abstract][Full Text] [Related]
20. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
